Spread the love

Emyria Limited  (Emyria or the Company), a data-backed drug development company, is proud to share this report on the Company’s activities for the quarter ending March 31, 2021.

Emyria’s Managing Director, Dr. Michael Winlo, said: “Emyria has started 2021 with great momentum. We have secured access to a unique CBD dose product via a partnership with Cann Group. Combined with our real world data and drug development expertise, Emyria is well positioned to commence our pivotal clinical trials, the important first steps towards successful registration of an over-the-counter CBD product with the TGA.

We have also boosted our advisory teams with the addition of Dr. Karen Smith and Dr. Richard Magtengaard.

Dr. Smith has overseen many successful Drug registration programs with the FDA and was recently Chief Medical Officer at Jazz Pharmaceuticals, notable for recently acquiring GW Pharma, a cannabinoid medicine company, for $US7.2B.

Dr. Magtengaard is a retired Naval officer and consultant psychiatrist with a passion for treating the mental health of veterans and first responders.

During the quarter, Emyria added two new clinical sites to support our pivotal trial programs and our plans to launch evidence-generating psychedelic-assisted therapy.

Emyria’s core remote monitoring technology was also recognised this quarter with a major grant award from the Western Australian Department of Health in partnership with collaborators at the University of Western Australia.

Finally, Emyria’s revenue figures for the quarter reflect the milestone nature of data deal payments but also our increased focus and investment into developing our primary strategic assets – those are our proprietary data and drug registration programs.”